日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis

CXCL9作为一种新型预后标志物,可用于识别噬血细胞性淋巴组织细胞增生症的高危成人患者

Rocco, Joseph M; Oved, Joseph H; Patel, Rikita J; Herskovits, A Zara; Nair, Namitha; Shakoory, Bita; Robertson, Thomas E; Dileo, Rachel; Jacobs, Max W; Zerbe, Christa S; Gordon, Rachael A; Ombrello, Michael J; Ombrello, Amanda K; Shah, Nirali N; Dimitrova, Dimana; Kanakry, Jennifer; Zelenetz, Andrew D; Moskowitz, Alison J; Stuver, Robert; Epstein-Peterson, Zachary D; Ghione, Paola; Mead, Elena; Shahid, Zainab; Raj, Sandeep; Park, Jae H; Giralt, Sergio A; Maillard, Ivan; Geyer, Mark B; Xiao, Wenbin; Dogan, Ahmet; Lim, Megan; Zwicker, Jeffrey I; Mones, Jodi; Parameswaran, Rehka; Banaszak, Lauren; Geller, Shamir; Santomasso, Bianca D; Shouval, Roni; Curran, Kevin J; Delmonte, Ottavia; Notarangelo, Luigi D; Cohen, Jeffrey I; Holland, Steven M; Salles, Gilles; Horwitz, Steven M; Vardhana, Santosha A; Perales, Miguel-Angel; Schwartz, Daniella; Sereti, Irini; Johnson, William T

Investigation of the hematological parameters in women with Interstitial Cystitis/Bladder Pain Syndrome and their relationship with disease severity

研究间质性膀胱炎/膀胱疼痛综合征女性患者的血液学参数及其与疾病严重程度的关系

Altan, Mehmet; Dogan, Ahmet Emin; Sandikci, Fatih; Cimen, Sertac

Impact of metabolic syndrome and its components on the tumor aggressiveness of renal cell carcinoma

代谢综合征及其组成部分对肾细胞癌肿瘤侵袭性的影响

Dogan, Ahmet Emin; Atan, Ali; Unsal, Ali; Polat, Fazli; Yesil, Suleyman

Validation of a Mass Spectrometry-Based Proteomics Molecular Pathology Assay

基于质谱的蛋白质组学分子病理学检测方法的验证

Chapman, Jessica R; Baik, Jeeyeon; Mereuta, Oana Madalina; Yi, Sansan; Walland, Ayal Cooper; Flor, Kristel; Wooten, Ashley; Wardrope, Jessica; Ritorto, Maria Stella; Dogan, Ahmet

CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53

CD4+ T 细胞淋巴瘤携带嵌合抗原受体整合于 TP53

Perica, Karlo; Jain, Nayan; Scordo, Michael; Patel, Ruchi; Eren, Ozgur Can; Patel, Utsav; Gundem, Gunes; Domenico, Dylan; Mitra, Sneha; Socci, Nicholas D; Everett, John K; Roche, Aoife M; Petrichenko, Angelina; Shah, Gunjan L; Arcila, Maria E; Borsu, Laetitia; Park, Jae H; Horwitz, Steven M; Giralt, Sergio A; Dogan, Ahmet; Leslie, Christina; Papaemmanuil, Elli; Bushman, Frederic D; Usmani, Saad Z; Sadelain, Michel; Mailankody, Sham

Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma

纳武利尤单抗联合多柔比星、长春碱、达卡巴嗪作为一线疗法治疗老年霍奇金淋巴瘤患者的II期临床试验

Torka, Pallawi; Feldman, Tatyana; Savage, Kerry J; Ganesan, Nivetha; Drill, Esther; Hancock, Helen; Davey, Theresa; Perez, Leslie; Capadona, Charisse; Subzwari, Sarima; Galasso, Natasha; Yang, Jinshu; Post, Michelle; Boardman, Alexander; Caron, Philip; David, Kevin; Epstein-Peterson, Zachary; Falchi, Lorenzo; Ghione, Paola; Hamlin, Paul; Horwitz, Steven M; Intlekofer, Andrew M; Johnson, William; Kumar, Anita; Lue, Jennifer; Noy, Ariela; Owens, Colette; Palomba, M Lia; Salles, Gilles A; Steiner, Raphael; Stuver, Robert; Vardhana, Santosha; Yahalom, Joachim; Dogan, Ahmet; Zelenetz, Andrew D; Schöder, Heiko; Moskowitz, Alison J

Phase I Trial of MCARH109, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated Analysis

MCARH109(一种靶向G蛋白偶联受体C类5成员D (GPRC5D) 的嵌合抗原受体T细胞疗法)治疗多发性骨髓瘤的I期临床试验:最新分析

Jurgens, Eric M; Firestone, Ross S; Chaudhari, Jagrutiben; Hosszu, Kinga; Devlin, Sean M; Shah, Urvi A; Landa, Jonathan; McAvoy, Devin P; Lesokhin, Alexander M; Korde, Neha; Hassoun, Hani; Tan, Carlyn R; Hultcrantz, Malin; Shah, Gunjan L; Landau, Heather J; Chung, David J; Scordo, Michael; Eren, Ozgur Can; Dogan, Ahmet; Giralt, Sergio A; Park, Jae H; Rivière, Isabelle; Brentjens, Renier J; Smith, Eric L; Wang, Xiuyan; Usmani, Saad Z; Mailankody, Sham

Temporal genomic dynamics shape clinical trajectory in multiple myeloma

时间基因组动态变化影响多发性骨髓瘤的临床病程

Maura, Francesco; Kaddoura, Marcella; Poos, Alexandra M; Baughn, Linda B; Ziccheddu, Bachisio; Bärtsch, Marc-Andrea; Cirrincione, Anthony; Maclachlan, Kylee; Chojnacka, Monika; Diamond, Benjamin; Papadimitriou, Marios; Blaney, Patrick; John, Lukas; Reichert, Philipp; Huhn, Stefanie; Gagler, Dylan; Zhang, Yanming; Dogan, Ahmet; Lesokhin, Alexander M; Davies, Faith; Goldschmidt, Hartmut; Fenk, Roland; Weisel, Katja C; Mai, Elias K; Korde, Neha; Morgan, Gareth J; Rajkumar, S Vincent; Kumar, Shaji; Usmani, Saad; Landgren, Ola; Raab, Marc S; Weinhold, Niels

Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation

扎努布替尼、奥妥珠单抗和维奈克拉用于一线治疗TP53突变型套细胞淋巴瘤

Kumar, Anita; Soumerai, Jacob; Abramson, Jeremy S; Barnes, Jeffrey A; Caron, Philip; Chhabra, Shalini; Chabowska, Maria; Dogan, Ahmet; Falchi, Lorenzo; Grieve, Clare; Haydu, J Erika; Johnson, Patrick Connor; Joseph, Ashlee; Kelly, Hailey E; Labarre, Alyssa; Lue, Jennifer Kimberly; Martignetti, Rosalba; Mi, Joanna; Moskowitz, Alison; Owens, Colette; Plummer, Sean; Puccio, Madeline; Salles, Gilles; Seshan, Venkatraman; Simkins, Elizabeth; Slupe, Natalie; Zhang, Honglei; Zelenetz, Andrew D

Defining 2 biologically and clinically distinct groups in acute leukemia with a mixed phenotype

在具有混合表型的急性白血病中定义 2 个生物学和临床上不同的组

Galera, Pallavi; Dilip, Deepika; Derkach, Andriy; Chan, Alexander; Zhang, Yanming; Persaud, Sonali; Mishra, Tanmay; Kramer, Kyle; Kathpalia, Mahak; Liu, Ying; Famulare, Christopher; Gao, Qi; Mata, Douglas A; Arcila, Maria; Geyer, Mark B; Stein, Eytan; Dogan, Ahmet; Roshal, Mikhail; Levine, Ross L; Glass, Jacob; Xiao, Wenbin